Substituted quinoxalines as FGFR kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9856236
SERIAL NO

14816565

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to new quinoxaline derivative compounds of formula (I),

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASTEX THERAPEUTICS LTDBRITAIN CAMB CAMBRIDGE CAMBRIDGESHIRE

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Angibaud, Patrick René Fontaine Bellenger, FR 59 1092
Berdini, Valerio Cambridge, GB 63 1305
Besong, Gilbert Ebai Bad Duerkheim, DE 20 516
Hamlett, Christopher Charles Frederick Cambridge, GB 14 405
Ligny, Yannick Aime Eddy Sotteville-les-Rouen, FR 11 251
Murray, Christopher William Cambridge, GB 61 981
Saxty, Gordon Zagreb, HR 55 1129
Woodhead, Steven John San Diego, US 32 655

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 2, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 2, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00